Jiangsu Hengrui Pharmaceuticals

Hengrui's HER2 ADC, approved in China for lung cancer and showing Enhertu-scale results in breast cancer, part of a wave of Chinese ADCs heading for global trials.

Pyrotinib is an irreversible pan-ErbB kinase inhibitor pill (EGFR, HER2, HER4) from Jiangsu Hengrui, approved in China since 2018 but not in the US or EU. It is the standard HER2 pill there, given with capecitabine after trastuzumab, and the comparator that new Chinese HER2 ADCs are beating; diarrhoea affects nearly every patient.

Camrelizumab is Jiangsu Hengrui's humanised PD-1 antibody, approved in China for oesophageal, liver and lung cancer but not in the US, where its liver cancer combination with rivoceranib drew complete response letters in 2024 and 2025 over manufacturing and inspection issues. Its signature side effect is reactive cutaneous capillary endothelial proliferation, a skin reaction seen in most patients.

A Chinese immunotherapy-plus-anti-angiogenic pill combination that clearly beat sorafenib in liver cancer, yet remains unapproved in the US after three manufacturing-related rejections.

Apatinib, sold as rivoceranib outside China, was the first pill of its kind approved for stomach cancer and is now the partner of camrelizumab in first-line liver cancer.

Dalpiciclib is Hengrui's CDK4/6 inhibitor, the first China-developed drug of the class, approved for hormone-driven advanced breast cancer on the DAWNA trials.

Adebrelimab is Hengrui's PD-L1 antibody, approved in China for first-line extensive-stage small cell lung cancer on the CAPSTONE-1 trial.

SHR-8068 is an experimental investigational agent whose form is not stated in the registry from Suzhou Suncadia Biopharmaceuticals in phase 3 trials for biliary tract cancer, non-small-cell lung cancer and cervical cancer, with its target not yet stated publicly.

SHR-A2102 is an experimental investigational agent whose form is not stated in the registry from Shanghai Hengrui Pharmaceutical in phase 3 trials for cervical cancer, non-small-cell lung cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.

HS-20093 is an experimental investigational agent whose form is not stated in the registry from Hansoh BioMedical R&D in phase 3 trials for osteosarcoma, non-small-cell lung cancer and sarcomas, with its target not yet stated publicly.

HRS-8080 is an experimental small-molecule drug from Shandong Suncadia Medicine in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.

SHR-A1921 is an experimental investigational agent whose form is not stated in the registry from Suzhou Suncadia Biopharmaceuticals in phase 3 trials for ovarian cancer, with its target not yet stated publicly.

SHR-1501 is an experimental investigational agent whose form is not stated in the registry from Suzhou Suncadia Biopharmaceuticals in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.

SHR-A2009 is an experimental investigational agent whose form is not stated in the registry from Shanghai Hengrui Pharmaceutical in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.

SHR-A1912 is an experimental investigational agent whose form is not stated in the registry from Suzhou Suncadia Biopharmaceuticals in phase 3 trials for diffuse large B-cell lymphoma, with its target not yet stated publicly.

HR070803 is an experimental small-molecule drug from Jiangsu HengRui Medicine in phase 3 trials for colorectal cancer, with its target not yet stated publicly.

HRS-4357 is an experimental investigational agent whose form is not stated in the registry from Jiangsu HengRui Medicine in phase 3 trials for prostate cancer, aimed at PSMA.

Mecapegfilgrastim is Hengrui's long-acting G-CSF, approved in China in 2018 to prevent chemotherapy-induced neutropenia.

Rezvilutamide is Hengrui's androgen receptor blocker, approved in China in 2022 for high-volume metastatic hormone-sensitive prostate cancer on the CHART trial, where it improved survival over bicalutamide.

Retlirafusp alfa is Hengrui's PD-L1 and TGF-beta bifunctional antibody, in phase 3 trials with chemotherapy in gastric cancer after the Western class leader bintrafusp alfa failed.